Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
23 pending office actions • 9 art units • 20 examiners • 0 of 23 (0%) have an AI response strategy ready • 28 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (4%) |
| §101 + other | 1 (4%) |
| §103 only | 7 (30%) |
| §112 only | 1 (4%) |
| Double-patenting + other | 4 (17%) |
| Multi-statute (no §101) | 8 (35%) |
| No statute on record | 1 (4%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARCORIA, PAUL JOSEPH | 2 | — | — |
| BRADLEY, CHRISTINA | 2 | 62.6% | +33.3% |
| CHANDRA, GYAN | 2 | 71.3% | +27.5% |
| CHONG, KIMBERLY | 1 | 72.4% | +13.0% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +38.9% |
| DABKOWSKI, ERINNE R | 1 | 55.9% | +69.0% |
| NAJARIAN, LENA | 1 | 38.9% | +39.2% |
| GALSTER, SAMUEL LEONARD | 1 | 50.9% | +43.2% |
| ANTHOPOLOS, PETER | 1 | 57.4% | +58.8% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.9% | +36.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19310993 | SEMAGLUTIDE FOR USE IN MEDICINE | DABKOWSKI, ERINNE R | 31d overdue |
| 18730933 | SYSTEMS AND METHODS FOR PERSONALIZED INSULIN TITRATION | NAJARIAN, LENA | 33d |
| 18837928 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | ARCORIA, PAUL JOSEPH | — |
| 18578485 | SODIUM N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLATE POLYMORPHIC FORM A | ANTHOPOLOS, PETER | — |
| 18252056 | COMPOUNDS AND THEIR USE IN TREATMENT OF TACHYKININ RECEPTOR MEDIATED DISORDERS | BRADLEY, CHRISTINA | — |
| 17782313 | FIXED DOSE INJECTION DEVICE | FARRAR, LAUREN PENG | — |
| 17782003 | AN INJECTION DEVICE FOR DELIVERING A LIQUID DRUG | NORTH, ISABELLA SARAH HYO SO | — |
| 17638483 | PROCESS FOR PRODUCING A TABLET COMPRISING GLP-1 PEPTIDES | HELLMAN, KRISTINA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19310993 | SEMAGLUTIDE FOR USE IN MEDICINE | DABKOWSKI, ERINNE R | 31d overdue |
| 18242868 | FACTOR X BINDERS ENHANCING FX ACTIVATION | SZPERKA, MICHAEL EDWARD | 5d overdue |
| 18730933 | SYSTEMS AND METHODS FOR PERSONALIZED INSULIN TITRATION | NAJARIAN, LENA | 33d |
| 19460949 | COMPOSITIONS AND METHODS FOR PROGRAMMED DEATH LIGAND RECEPTOR (PD-L1) EXPRESSION | CHONG, KIMBERLY | — |
| 19378410 | SEMAGLUTIDE IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 18723131 | PROCESS FOR THE BACKBONE DEPROTECTION OF OLIGONUCLEOTIDES CONTAINING A TERMINAL ALKYL PHOSPHONATE GROUP | GALSTER, SAMUEL LEONARD | — |
| 18673424 | Combination Therapy for Treatment of Liver Disease | BRADLEY, CHRISTINA | — |
| 18591754 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | CHANDRA, GYAN | — |
| Art Unit | Apps |
|---|---|
| 3783 | 5 |
| 1654 | 4 |
| 1658 | 2 |
| 1626 | 2 |
| 1636 | 1 |
| 3687 | 1 |
| 1641 | 1 |
| 1632 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19460949 | COMPOSITIONS AND METHODS FOR PROGRAMMED DEATH LIGAND RECEPTOR (PD-L1) EXPRESSION | CHONG, KIMBERLY | 1636 | — | Non-Final OA | — | Pending | Jan 27, 2026 |
| 19378410 | SEMAGLUTIDE IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103§112DP | Final Rejection | — | Pending | Nov 04, 2025 |
| 19310993 | SEMAGLUTIDE FOR USE IN MEDICINE | DABKOWSKI, ERINNE R | 1654 | §101 | Final Rejection | 31d overdue | Pending | Aug 27, 2025 |
| 18839945 | METHODS FOR TREATING SUBJECTS WITH ABDOMINAL OBESITY HYPERTRIGLYCERIDEMIA AND/OR IMPAIRED GLUCOSE | ARCORIA, PAUL JOSEPH | — | §103 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18837928 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | ARCORIA, PAUL JOSEPH | — | §103§112 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18730933 | SYSTEMS AND METHODS FOR PERSONALIZED INSULIN TITRATION | NAJARIAN, LENA | 3687 | §101§103§112 | Non-Final OA | 33d | Pending | Jul 22, 2024 |
| 18723131 | PROCESS FOR THE BACKBONE DEPROTECTION OF OLIGONUCLEOTIDES CONTAINING A TERMINAL ALKYL PHOSPHONATE GROUP | GALSTER, SAMUEL LEONARD | — | §103 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18673424 | Combination Therapy for Treatment of Liver Disease | BRADLEY, CHRISTINA | 1654 | §103 | Non-Final OA | — | Pending | May 24, 2024 |
| 18591754 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | CHANDRA, GYAN | — | §112DP | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18426412 | GLP-1 RECEPTOR AGONISTS IN DEMENTIA | CHANDRA, GYAN | — | §102§103DP | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18578485 | SODIUM N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLATE POLYMORPHIC FORM A | ANTHOPOLOS, PETER | 1626 | §102§103§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18242868 | FACTOR X BINDERS ENHANCING FX ACTIVATION | SZPERKA, MICHAEL EDWARD | 1641 | §112DP | Final Rejection | 5d overdue | Pending | Sep 06, 2023 |
| 18252056 | COMPOUNDS AND THEIR USE IN TREATMENT OF TACHYKININ RECEPTOR MEDIATED DISORDERS | BRADLEY, CHRISTINA | 1654 | §103§112 | Non-Final OA | — | Pending | May 08, 2023 |
| 17913292 | Solid Dispersions of Amorphous 3,4-Diphenyl-4,5-Dihydro-1H-Pyrazole Derivatives, Compositions Comprising them and Uses Thereof as Cannabinoid CB1 Receptor Inhibitors | SAEED, KAMAL A | 1626 | §112 | Final Rejection | — | Pending | Sep 21, 2022 |
| 17782313 | FIXED DOSE INJECTION DEVICE | FARRAR, LAUREN PENG | 3783 | §102§103 | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17782003 | AN INJECTION DEVICE FOR DELIVERING A LIQUID DRUG | NORTH, ISABELLA SARAH HYO SO | 3783 | §102§103 | Non-Final OA | — | Pending | Jun 02, 2022 |
| 17638483 | PROCESS FOR PRODUCING A TABLET COMPRISING GLP-1 PEPTIDES | HELLMAN, KRISTINA M | 1654 | §102§112Other | Final Rejection | — | Pending | Feb 25, 2022 |
| 17616283 | APPLICATION OF ANTIARRHYTHMIC AGENTS TO STEM CELL DERIVED CARDIOMYOCYTES AND USES THEREOF | TRAN, KHOA NHAT | 1632 | §103 | Final Rejection | — | Pending | Dec 03, 2021 |
| 17614077 | DUAL CHAMBER DRUG RESERVOIR AND STOPPER THEREFOR | RITCHIE, HADEN MATTHEW | 3783 | §102§103 | Final Rejection | — | Pending | Nov 24, 2021 |
| 17403357 | COMPOSITIONS COMPRISING A DELIVERY AGENT AND PREPARATION THEREOF | REYNOLDS, FRED H | 1658 | §103§112Other | Non-Final OA | — | Pending | Aug 16, 2021 |
| 17424537 | ROLLER COMPACTOR AND METHOD OF DRY GRANULATION USING A ROLLER COMPACTOR | ROGERS, JAMES WILLIAM | 1618 | §103 | Non-Final OA | — | Pending | Jul 21, 2021 |
| 17418176 | DRUG RESERVOIR FOR SEPARATE STORAGE OF SUBSTANCES | DIPERT, FORREST BLAKE | 3783 | §103 | Final Rejection | 33d | Pending | Jun 24, 2021 |
| 17286639 | ZERO-POINT ADJUSTMENT OF PREFILLED DRUG DELIVERY DEVICE | ZAMORY, JUSTIN L | 3783 | §103 | Final Rejection | — | Pending | Apr 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial